Lilly and Incyte Provide Update on Supplemental New Drug Application for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis

Eli Lilly and Company and Incyte announced that the US FDA will not meet the Prescription Drug User Fee Act action date for the supplemental new drug application for baricitinib for the treatment of adults with moderate to severe atopic dermatitis (AD).